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.2011.08.0Abstract Emulsiﬁcation/internal gelation has been suggested as an alternative to extrusion/exter-
nal gelation in the encapsulation of several compounds including non-steroidal anti-inﬂammatory
drugs such as diclofenac sodium. The objective of the present study was a trial to formulate diclofe-
nac sodium as controlled release microparticles that might be administered once or twice daily. This
could be achieved via emulsiﬁcation/internal gelation technique applying Box-Behnken design to
choose these formulae. Box-Behnken design determined ﬁfteen formulae containing speciﬁed
amounts of the independent variables, which included stirring speed in rpm (X1), drug:polymer
ratio (X2) and the surfactant span 80% (X3). The dependent variables studied were cumulative per-
cent release after two hours (Y1), four hours (Y2) and eight hours (Y3). The prepared microparticles
were characterized for their production yield, sizes, shapes and morphology, entrapment efﬁciency
and Diclofenac sodium in vitro release as well. The results showed that the production yield of the
prepared diclofenac sodium microparticles was found to be between 79.55% and 97.41%. The for-
mulated microparticles exhibited acceptable drug content values that lie in the range 66.20–96.36%.
Also, the data obtained revealed that increasing the mixing speed (X1) generally resulted in
decreased microparticle size. In addition, scanning electron microscope images of the microparticles
illustrated that the formula contains lower span concentration (1%) in combination with lower stir-
ring speed (200 rpm) which showed wrinkled, but smooth surfaces. However, by increasing surfac-
tant concentration, microspheres’ surfaces become smoother and slightly porous. Kinetic treatment
of the in vitro release from drug-loaded microparticles indicated that the zero order is the drug
release mechanism for the most formulae.
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041. Introduction
Emulsiﬁcation/internal gelation has been suggested as an
alternative to extrusion/external gelation in the encapsulation
of several compounds including sensitive biologicals such as
protein drugs. An emulsiﬁcation/internal gelation method is
proposed for producing small diameter alginate microspheres
in large quantity. The difﬁculty in using dispersion/external
gelation techniques with ionic polysaccharide is that theier B.V. All rights reserved.
62 M.M. Ahmed et al.calcium source (CaCl2) is insoluble in the oil phase. As an
alternative, internal gelation of the dispersed alginate droplets
may be initiated by releasing Ca2+ from an insoluble complex
(calcium salt) through pH reduction (Friese et al., 2000; Gref
et al., 2001). Diclofenac sodium has analgesic, antipyretic and
anti-inﬂammatory properties. It is an inhibitor of prostaglan-
din synthetase. It is used for the relief of pain and inﬂamma-
tion in conditions such as rheumatoid arthritis, osteoarthritis,
acute gout and following some surgical procedures. The usual
dose by mouth is 75–150 mg daily in divided doses (Sanchez
et al., 2003). By controlling the conditions under which the
water-in oil dispersion is produced, the bead size can be con-
trolled from a few microns to millimeters in diameter. Biode-
gradable polymeric particles, especially microparticles and
nanoparticles, have attracted considerable attention as poten-
tial drug controlled delivery devices (Catarina et al., 2006; Qiu
and Park, 2001; Silva et al., 2006). Alginates, which are natu-
rally occurring substances found in brown seaweed and algae
have received much attention in pharmaceutical dosage forms,
particularly as a vehicle for controlled drug delivery (Chen and
Subirade, 2007). Alginates can be considered as block polymers,
which mainly consist of mannuronic acid (M), guluronic acid
(G) and mannuronic–guluronic (MG) blocks. One of the meth-
ods under consideration for the production of these drug deliv-
ery systems is emulsiﬁcation/internal gelation. In this context,
the use of alginate microcapsules as oral delivery system for
NSAIDs seems very attractive. First, the alginate matrix could
protect the drug from hostile environments (Chan et al., 2002).
Second, alginate possesses mucoadhesive properties which
could increase the contact time between microcapsules and
absorptive sites, and therefore, could enhance the uptake of
encapsulated drug (Guan et al., 2001). Third, biodegradable
alginate microcapsules may show variable release kinetics
(Perumal, 2001). Fourth, the low toxicity and low immunoge-
nicity of alginate make this polymer a safe matrix (Chan
et al., 2002). Fifth, alginate is readily available and inexpensive.
Therefore, the goal of this study was to prepare, optimize
and fully characterize diclofenac sodium loaded alginate
microcapsules. The effect of some factors, such as drug:poly-
mer ratio, concentration of span 80 and the stirring speed on
the mean particle size, microparticles yield, drug release and
drug entrapment efﬁciency of the resulting diclofenac–alginate
microparticles was investigated. In addition, the study aims to
outline the use of the emulsiﬁcation/internal gelation for
microencapsulation of diclofenac sodium, with particular ref-
erence to the use of alginate as the polymer matrix.
2. Experimental materials
Diclofenac sodium and Sodium alginate (MWt 216) were pur-
chased from Sigma chemical Co. (NJ, USA). Span 80 was ob-
tained from Fluka Chemica (Buch, Switzerland). Parafﬁn oil
(heavy) was obtained from El-Nasr Co. (Abu-Zabal, Cairo
Egypt). Polysorbates 80 (Tween 80) was purchased from
BDH chemical Ltd. Co. (Poole, England). Other materials
and solvents are of reagent or analytical grade, and they were
used without further puriﬁcation.
2.1. Design of the experiment
A Box-Behnken design was selected for formulating diclofenac
sodiummicroparticles with the following independent variables:stirring speed, rpm, (X1), drug:polymer ratio (X2) and span 80%
(X3). Three levels (1, 0 and + 1) of each independent variable
were used for the above design. The values of the corresponding
variables were 200, 400 and 600 rpm for the machine stirring
speed; 1:1, 1:2 and 1:3 for drug–polymer ratio and 1%, 1.5%
and 2% for span 80%. The effect of these three factors; namely,
drug to polymer ratio, span 80 concentration and the speed of
stirring on the microparticles attributes was studied.
2.2. Preparation of alginate coated microparticles
Composition of different suggested formulae of diclofenac so-
dium microparticles is listed in Table 1. A basal encapsulation
protocol was used to prepare microparticles (Silva et al., 2006).
In brief, different concentrations of sodium alginate solution
were prepared by dissolving the speciﬁed amount of the poly-
mer (0.5–1.5 gm) in 30 ml hot water and then diclofenac so-
dium was dispersed in this solution using a magnetic stirrer
(Stuart SM27, Dublin, Ireland) for 10 min. The concentrations
of diclofenac sodium to sodium alginate were prepared in dif-
ferent drug:polymer ratios 1:1, 1:2 and 1:3. A suspension of
CaCO3 at 5% (w/v) was added to the alginate-diclofenac so-
dium solution, after homogenization (Mechanika Precyzyjna-
MPW-309, Poland), the mixture was dispersed into parafﬁn
oil (30% internal phase ratio, v/v) containing different concen-
trations of span 80 as emulsifying agent and was emulsiﬁed by
stirring at different speeds. After emulsiﬁcation for 15 min,
20 ml of parafﬁn oil containing 0.2 ml glacial acetic acid
(acid/Ca molar ratio of 3.5) were added to the w/o emulsion
and stirring was continued to permit calcium carbonate solubi-
lization (Chen and Subirade, 2007). A solution of CaCl2
(0.05 M) containing 1% Tween 80 was added to the partition
to recover the gelled microspheres from oily phase by
decantation. Microparticles were washed with 0.05 M CaCl2
containing 1% Tween 80 to remove residual oil. Microparticles
were recovered from oily phase by using an acetate buffer at pH
4.5 and successively washed with this buffer until no more oil
was detected by optical microscope observation. A sample of
the prepared microparticles for all formulae is examined under
optical microscope to detect the presence of oil droplets. Fur-
thermore a sample of the prepared microparticles is pressed be-
tween two ﬁlter papers to detect the presence of any oily
droplets. Microparticles were dried for 48 h at room tempera-
ture and stored in a dessicator until starting experiment. The
experiment was repeated three times for each formula.
2.3. Production yield determination
The yield of the microparticles was determined in triplicate by
dividing the weight of the prepared microparticles by the origi-
nal amount of the polymer and drug used and the results were
expressed as a percentage according to the equation (Jelvehgari
et al., 2010):
% Yield ¼
ðActual weight of product=Total weight of excipient and drugÞ  1002.4. Particle size determination
The dried microparticles were weighed and sized using USP
standard sieve set (Rx-86-1, Cole-Parmer Instrument Co.,
USA). The fraction of microparticles remaining on each sieve
Table 1 Composition of different suggested formulae of diclofenac sodium microparticles using sodium alginate according to
pharmaceutical point of view.
Formula No. Drug (gm) Sodium alginate (gm) Calcium carbonate (gm) Liquid paraﬃn (ml) Span 80 (ml) Speed (rpm) Total weight (gm)
F1 0.5 0.5 0.375 100 1.5 200 1.375
F2 0.5 0.5 0.375 100 1.0 400 1.375
F3 0.5 0.5 0.375 100 2 400 1.375
F4 0.5 0.5 0.375 100 1.5 600 1.375
F5 0.5 1 0.375 100 1.0 200 1.875
F6 0.5 1 0.375 100 2 200 1.875
F7 0.5 1 0.375 100 1.5 400 1.875
F8 0.5 1 0.375 100 1.5 400 1.875
F9 0.5 1 0.375 100 1.5 400 1.875
F10 0.5 1 0.375 100 1.0 600 1.875
F11 0.5 1 0.375 100 2 600 1.875
F12 0.5 1.5 0.375 100 1.5 200 2.375
F13 0.5 1.5 0.375 100 1.0 400 2.375
F14 0.5 1.5 0.375 100 2 400 2.375
F15 0.5 1.5 0.375 100 1.5 600 2.375
Speed +1= 600 0 = 400 1 = 200
Drug: polymer ratio +1 = 1:3 0 = 1:2 1 = 1:1
Span 80% +1= 2% 0= 1.5% 1 = 1%
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was assigned as the percentage ofmicroparticles retained at each
sieve multiplied by the average particle size of the sieve used
(Choi et al., 2002). Each experiment was carried out in triplicate.
2.5. Determination of drug content
Thedrug content of the prepareddiclofenac sodiummicroparticles
was determined by the digestion method (Perumal, 2001;
Jelvehgari et al., 2010) and the experimentswere carried out in trip-
licate. One hundred micrograms of diclofenac sodiummicroparti-
cles was crushed carefully in a glass mortar and a deﬁnite weight
was transferred toa100 mlvolumetric ﬂaskusingphosphatebuffer
pH 7.4. The volumetric ﬂask was completed to the volume with
phosphate buffer pH 7.4 then agitated for 5 min each hour for
5 h. The sample was ﬁltered and the drug concentrationwas deter-
mined spectrophotometerically at 277 nm (Spectrophotometer
UV. 1601, Shimadzu Co., Japan). The same procedure was ap-
plied for the plain formula, which was used as a blank.
2.6. Microparticles morphology by scanning electron microscopy
The morphology of the microparticles surfaces was investi-
gated using scanning electron microscopy. Microspheres were
spread on a carbon double-adhesive layer on a metal holder
and gold-coated using Ion-Sputtering device (Jeol Fine-Coat
JFC 1100E, Jeol Ltd., Tokyo, Japan). The microparticles were
scanned by Scanning Electron Microscope (SEM) (Jeol JSM-
5400 LV, Jeol Ltd., Tokyo, Japan).
2.7. In vitro release of diclofenac sodium microparticles
Dissolution testing of the prepared microparticles equivalent
to 100 mg of diclofenac sodium was performed with the rotat-
ing basket apparatus according to USP 24 apparatus 1 (SR11 6
Flask, Hanson Co., USA). Hard gelatin capsules No. 2 ﬁlled
with known amount of microparticles were used for dissolu-
tion testing using basket speed of 50 rpm and a temperatureof 37 C± 0.5. Regarding the dissolution medium, the pH
shift method (Mahrous et al., 2010) was used. First, 500 ml
of 0.1 N HCl pH 1.2, was used as the release medium for
two hours, followed by addition of (14.25) milliliters of 7 M
potassium dihydrogen orthophosphate containing 16.75%
(w/v) NaOH in order to change the pH of the medium to 7.4
and the experiment was continued for another six hours. Three
milliliters of each sample were removed at speciﬁc intervals
throughout the whole 8 h (0.25, 0.5, 1, 1.5, 2, 2.25, 2.5, 3, 4,
5, 6, 7 and 8 h). The samples were diluted appropriately with
the release medium and absorbance was measured at the pre-
determined kmax of each medium against a blank of this med-
ium. The withdrawn samples were replaced with equal volumes
of the release medium. It is worthy to mention that the exper-
iments were carried out in triplicate.
2.8. Kinetics of the in vitro release of diclofenac sodium capsules
The kinetic parameters for the in vitro release of diclofenac so-
dium were determined and then analyzed in order to ﬁnd the
proper order of the drug release using a speciﬁc computer pro-
gram (Stategraph plus). Zero and ﬁrst order kinetics, as well as
controlled diffusion or Higuchi diffusion model (Higuchi et al.,
1963), in addition to Hixson-Crowell cube root law (Hixon
and Crowel, 1977) and Baker-Lonsdale equation (Baker and
Lonsdale, 1974) were investigated.
3. Results and discussion
3.1. Experimental design
Box-Behnken design, as shown in Table 1, was used for formu-
lating diclofenac sodium microparticles (Kramar et al., 2003)
deals with optimization of formulation variables to improve
the in vitro release of dosage forms. The three independent vari-
ables are stirring speed (X1), drug:polymer ratio (X2) and span
80% (X3). According to Box-Behnken design, 15 formulae of
Diclofenac sodium-loaded microparticles were prepared.
Table 2 Production yield and percentage recovery (drug content) of diclofenac sodium–sodium alginate microparticles.
Formula No. Drug–polymer ratio Production yield% Theoretical drug content (gm) Actual drug content (gm) Drug content%
F1 1:1 93.70 ± 3.67 50.00 46.49 ± 1.96 92.98 ± 3.92
F2 1:1 92.90 ± 4.26 50.00 45.90 ± 2.22 91.80 ± 4.44
F3 1:1 83.93 ± 3.78 50.00 33.51 ± 3.45 66.20 ± 6.90
F4 1:1 81.82 ± 5.01 50.00 37.83 ± 3.34 75.66 ± 6.68
F5 1:2 96.75 ± 4.21 33.33 32.11 ± 2.01 96.36 ± 4.02
F6 1:2 85.02 ± 2.98 33.33 23.40 ± 1.97 70.21 ± 3.94
F7 1:2 88.39 ± 3.65 33.33 25.23 ± 2.46 81.69 ± 4.92
F8 1:2 90.25 ± 4.46 33.33 29.55 ± 3.12 88.65 ± 6.24
F9 1:2 88.54 ± 3.98 33.33 29.05 ± 2.46 87.15 ± 4.92
F10 1:2 86.90 ± 4.34 33.33 24.51 ± 2.34 73.53 ± 4.68
F11 1:2 79.55 ± 3.87 33.33 26.12 ± 2.18 78.36 ± 4.36
F12 1:3 89.07 ± 4.22 25 23.82 ± 1.24 95.28 ± 2.48
F13 1:3 97.41 ± 4.78 25 22.26 ± 1.66 89.04 ± 3.32
F14 1:3 82.29 ± 3.66 25 19.71 ± 2.08 78.84 ± 4.16
F15 1:3 85.30 ± 4.44 25 21.17 ± 1.68 84.68 ± 3.36
Table 3 Fraction percent of weight distribution of different formulae of diclofenac sodium–sodium alginate microparticles.
Formula No. Fraction percent of weight distribution in:
890–630 lm 630–400 lm 400–315 lm 315–200 lm 200–160 lm 160–100 lm
F1 27.72 29.85 16.33 19.76 3.38 2.963
F2 14.68 29.59 29.35 14.88 9.0 2.5
F3 17.29 33.513 24.97 12.865 5.941 5.421
F4 8.04 29.78 18.67 29.33 11.29 2.56
F5 32.68 25.58 15.55 20.27 5.53 0.39
F6 29.73 28.59 14.58 16.57 5.75 4.78
F7 16.42 27.24 26.05 20.74 4.68 4.87
F8 15.24 27.08 23.12 25.67 5.24 3.65
F9 13.32 30.01 12.70 28.31 9.77 5.89
F10 5.25 22.37 32.65 19.76 14.29 5.68
F11 6.66 22.62 19.73 27.65 15.89 7.45
F12 22.26 31.05 16.21 22.25 5.01 3.22
F13 13.55 19.46 18.05 32.54 7.54 8.86
F14 11.60 21.50 16.54 35.86 7.45 7.05
F15 9.79 27.80 15.69 31.13 11.34 4.24
Figure 1 Scanning electron micrograph of diclofenac sodium–sodium alginate microparticles, F5, F7.
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Figure 2 In vitro release of diclofenac sodium–sodium alginate
capsules containing drug:polymer ratio 1:1.
Figure 3 In vitro release of diclofenac sodium–sodium alginate
capsules containing drug:polymer ratio 1:2.
Figure 4 In vitro release of diclofenac sodium–sodium alginate
capsules containing drug:polymer ratio 1:3.
Figure 5 Three dimensional contour plots for the effect of speed
(X1), drug–polymer ratio (X2) and Span 80% (X3) on the
cumulative percent release after two hours (Y1).
Emulsiﬁcation/internal gelation as a method for preparation 65Three levels of the speed were used; 200, 400 and 600 rpm
denoted the values 1, 0 and +1 in the above design, respec-
tively. Drug:polymer ratio was varied to be 1:1, 1:2 and 1:3,also denoted the values 1, 0 and +1, respectively. Moreover,
span 80% was chosen to be 1%, 1.5% and 2%, denoted 1, 0
and +1 value, respectively. The chosen dependent variables to
be tested for the prepared microparticles were the in vitro re-
lease of the drug capsules after 2 h (Y1), 4 h (Y2) and 8 h (Y3).
3.2. Production yield determination
The range of the production yield of the prepared diclofenac
sodium microparticles was found to be between 79.55% and
97.41% as shown in Table 2. The highest microparticles crop
was obtained in case of formula 13 (97.41%), in which stirring
speed was intermediate value (400 rpm) in combination with
lower span concentration (1%) and increasing the polymer
weight ratio as well. By applying the highest stirring speed
(600 rpm) in combination with the highest span concentration
(2%), a lowest microparticles yield was obtained as the case of
formula 11 (79.55%).
3.3. Microparticles drug content
The drug content determination measures the actual loaded
weight of diclofenac sodium inside the microparticles. Micro-
particles formulated by using slow stirring rate (200) in combi-
nation with lower or intermediate span concentrations were
found to have higher drug contents (as the case of formula-
tions F5, F12, F1), Table 2. On the other hand, microparticle
Figure 6 Three dimensional contour plots for the effect of speed
(X1), drug–polymer ratio (X2) and Span 80% (X3)) on the
cumulative percent release after four hours (Y1).
66 M.M. Ahmed et al.formulations prepared by using higher stirring speeds and/or
higher span concentrations exhibited lower drug contents, as
the case of F3 (66.2%). Alipour et al. (2010) showed that
microencapsulation by the emulsiﬁcation/gelation method in-
volves two major steps, the formation of stable droplets of
the polymer solution with drug incorporated in as an emulsi-
ﬁed system and the subsequent solidiﬁcation of the droplets.
These two steps have a signiﬁcant effect on size and encapsu-
lation efﬁciency of microparticles.
3.4. Particle size distribution
The fraction percent of weight distribution of different for-
mulae of diclofenac sodium–sodium alginate microparticles
determined by sieve analysis is illustrated in Table 3. The
range of sieve employed ranged from 890 to 100 lm. The
narrowest distribution patterns were observed in an ascend-
ing order for formulae F11, F10, F14, F13 and F15, in
which the microparticle sizes lay in the range 315–200 lm.
An intermediate distribution proﬁle was recorded with F10
(400–315 lm). In addition, the fraction percent of the ﬁnes
(160–100 lm) was found to increase by increasing span con-
centration and stirring speed (F7), Table 3. Moreover, slight
increases in the microparticle sizes were detected in formulae
F4, F9, F8, F7, F2, F3, F12, and F1, in which particle sizesin the range of 630–400 lm were exhibited. Furthermore, the
microparticles sizes of formulae F5 and F6 were found to be
the largest (890–630 lm). Stirring speed is the most impor-
tant parameter for controlling the drug/matrix dispersion’s
droplet size in the continuous phase. It was shown that
increasing the stirring speed generally results in decreased
microparticle size, as it produces smaller emulsion droplets
through stronger shear forces and increased turbulence
(Perumal, 2001).
In this study, the high stirring speed (600 rpm) produced
microparticles with small particle size while the lower stirring
speed (200 rpm) produced large sized microparticles.
3.5. Microparticles’ shapes and surfaces (SEM)
Scanning electron microscopy was used to characterize the
shapes and the surfaces of the prepared diclofenac sodium
microparticles. Fig. 1 displays the SEM images of the formula-
tions F5 and F7 as representatives of all microparticles formu-
lae. For comparison, F5 (1% span and 200 rpm stirring)
microparticles showed rough and irregular surfaces and no
aggregation was observed. Upon increasing the span concen-
tration and stirring speed, as the case of F7 (1.5% span and
400 rpm stirring), microparticles’ surfaces become more
smooth and slightly porous.
3.6. In vitro release of diclofenac sodium microparticles
The in vitro release of diclofenac sodium from its-loaded algi-
nate microparticles was evaluated by measuring the cumulative
percent release. The results showed that at pH 1.2, all the
microparticles were retained intact nearly without swelling.
This behavior depends on the nature of the used polymer.
Fig. 2 shows the in vitro release of diclofenac sodium from
its-loaded microparticles containing formulae (F1–F4) using
constant drug:polymer ratio 1:1 (X2) with variable span 80,
1% for F2; 1.5% for F1 and F4; 2% for F3 (X3), and the var-
iable speeds; 200 rpm for F1; 400 rpm for F2 and F3; 600 rpm
for F4 (X1). The results showed that the in vitro drug release
from these formulae is biphasic under the control of dissolu-
tion medium pH. In the acidic region, no swelling could be ob-
served for microparticles formulations, which slowed the drug
release rate (not more than 16% of the loaded drug was re-
leased). In addition, the very poor solubility of diclofenac so-
dium plays an important role in retarding its release from
microparticles in the acidic medium (Higuchi et al., 1963). In
contrast, upon shifting the release medium to the alkaline re-
gion, a pronounced enhancement was detected in the drug re-
lease rate, as a result of microparticles swelling and increased
drug solubility. The maximum and minimum percent released
were observed to be 15.43% and 8.46% at the end of two
hours for formulae F14 and F2, respectively (Y1). After eight
hours of dissolution (Y3), 100% was released for the afore-
mentioned two formulae. It has been reported that the swelling
can be enhanced in the presence of phosphate ions which act as
calcium sequestrates. The exchange of the divalent calcium in-
volved in electrostatic links between various carboxylate moi-
eties of the alginate chain, with the monovalent sodium leads
to an increased osmotic pressure inside the gel, causing it to
swell. The swelling of the alginate impregnated in the micro-
particles increased their porosity, thereby allowing the quick
release (Al-Kassas et al., 2007).
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ticles containing formulae F5-F11 is illustrated in Fig. 3. Dif-
ferent formulation variables were studied in these formulae
including drug:polymer ratio (X2), span 80 concentration
(X3), and stirring speed (X1). The maximum and minimum
percent released were observed to be 16.99% and 8.40% re-
leased at the end of two hours (Y1), while 83.34% and
60.76% release values were recorded after four hours for F6
and F11, respectively. After eight hours of dissolution (Y3),
100% and 94.22% were released for the aforementioned two
formulae.
Moreover, Fig. 4 illustrates the in vitro release of diclofenac
sodium from its-loaded microparticles made of a higher so-
dium alginate concentration (1.5%), i.e., formulae F12-F15,
using constant drug:polymer ratio (1:3) (X2) with varying both
span 80 weight ratio (X3) and stirring speed (X1). Combina-
tion of higher span concentration with lower and medium stir-
ring speed resulted in slower in vitro release rates in the
alkaline pH (F14 and F12). In contrast, fast release rates were
observed with the formulae prepared by using lower and med-
ium span 80 concentrations in combination of higher speed
values (F15 and F13).
Silva et al. (2006) noted that increasing alginate concentra-
tion caused a slightly higher retention of insulin at pH 1.2.
They also observed that insulin release in acidic medium de-
creased when alginate concentration was increased.Figure 7 Three dimensional contour plots for the effect of speed
(X1), drug–polymer ratio (X2) and Span 80% (X3) on the
cumulative percent release after eight hours.From Table 4 and Figs. 5-7, it could be concluded that by
increasing X2 and decreasing X1, the drug release (Y3) de-
creased at ﬁxed X3 levels. This indicates a negative correlation
between Y3 and X2, Figs. 5-7(B). In addition, at lower and
medium X3 levels and at all X2 levels, the increase in X1 level
did not prevail an observable change in the in vitro release rate
(Y3). However, the effect of increasing X1 level on the in vitro
release rate is only pronounced at medium and higher X2
and X3 levels indicating a positive correlation between Y3
and X1. For example, when X2 was ﬁxed at medium level
(1:2) and X3 at high level (2%), Y3 increased from 85.44%
to 95.82% by increasing X1 from low level (200 rpm) to high
level (600 rpm).
Moreover, the effect of increasingX2 level on the in vitro release
rate (Y3) could be noticeable only at a higherX1 level in combina-
tion with medium and higher X2 levels. For example, when X2 at
high level (1:3) was used, Y3 decreased from 83.65% to 55.63%
when X3 increased from low level (1%) to high level (2%). Also,
at ﬁxedhigherX1 level (600 rpmhigh level) andatmediumX2 level
(1:2),Y3 decreased from100%to 95.82%whenX3 increased from
low level (1%) to high level (2%).
The results obtained indicated the insigniﬁcant effect of
span 80% (X3), signiﬁcant effect of speed and drug–polymer
ratio, so speed must be in low level (200 rpm) while drug–poly-
mer ratio must be in high level (1:3).
From the above discussed results, the best value having the
minimum drug release after 4 h (Y2) appears in formula F14
(45.26%) when X1 is at medium speed (400 rpm), X2 at high
level (1:3) and X3 at high level (2%).3.7. Kinetics of in vitro release of diclofenac sodium
microparticles
The kinetic treatment was done by plotting the time in hours
versus the cumulative percent released of diclofenac sodium
for zero, ﬁrst, Hixson-Crowell cube root low and Baker-Lons-
dale equation. The kinetic treatment for Higuchi diffusion
model was calculated by plotting the square root of time in
hours versus the cumulative percent of diclofenac sodium re-
lease. The calculated correlation coefﬁcient values for the
in vitro release of the drug from its-loaded microparticles indi-
cate that the zero order is the drug release mechanism, Table 5.
An exception was observed in case of F3, in which the release
mechanism was found to follow ﬁrst-order with t1/2 of 2.64 h,
Table 5. The t1/2 values for formulations F1, F2, F4, F5, F6,
F7, F8, F9, F10, F11, F12, F13, F14 and F15 were found to
be 2.854, 2.187, 2.42, 2.72, 2.8, 2.77, 2.79, 2.6, 2.55, 2.36,
3.49, 3.34, 4.04 and 3.27 h, respectively.4. Conclusion
Diclofenac sodium-loaded alginate microparticles were suc-
cessfully obtained by emulsiﬁcation/internal gelation, which
is a simple and economic method for microencapsulation. Stir-
ring speed is the most effective parameter for controlling the
drug/matrix dispersion’s droplet size in the continuous phase,
so it must be in low level (200 rpm). In addition, drug:polymer
ratio must be at high level (1:3), while span 80 has no signiﬁ-
cant effect. The drug release from the most prepared sodium
alginate microparticles was found to follow zero order kinetics,
which is optimum for the controlled drug delivery.
Table 5 The calculated correlation coefﬁcient values and zero order kinetic parameters for the in vitro release of diclofenac sodium–
sodium alginate capsules employing different kinetic orders or systems.
Formula Zero order First order Higuchi Hixon-Crowel B-L (t1/2) h Kinetic rate constant
F1 0.942 0.905 0.879 0.919 0.953 2.854 17.51
F2 0.953 0.923 0.916 0.942 0.898 2.187 22.85
F3 0.909 0.901 0.833 0.132 0.201 2.64 1.081
F4 0.955 0.922 0.910 0.939 0.894 2.42 20.57
F5 0.973 0.902 0.912 0.934 0.814 2.72 18.36
F6 0.974 0.913 0.915 0.942 0.878 2.80 17.80
F7 0.967 0.859 0.902 0.904 0.811 2.77 17.98
F8 0.975 0.892 0.919 0.935 0.879 2.79 17.90
F9 0.959 0.868 0.888 0.907 0.825 2.60 19.21
F10 0.974 0.943 0.928 0.956 0.873 2.55 19.59
F11 0.958 0.912 0.934 0.950 0.897 2.36 21.15
F12 0.976 0.957 0.939 0.972 0.924 3.49 14.30
F13 0.986 0.933 0.961 0.972 0.927 3.34 14.95
F14 0.973 0.884 0.920 0.924 0.884 4.04 12.76
F15 0.982 0.940 0.950 0.965 0.898 3.27 15.28
Table 4 Observed values of responses for the Box-Behnken design of diclofenac sodium–sodium alginate capsules.
Formula Variable level in coded form Cumulative percent release
X1 X2 X3 Y1 (2 h) Y2 (4 h) Y3 (8 h)
F1 1 1 0 8.46 74.56 74.56
F2 0 1 1 15.43 100 100
F3 0 1 +1 12.34 92.70 92.70
F4 +1 1 0 14.56 88.65 88.65
F5 1 0 1 10.77 68.65 100
F6 1 0 +1 8.40 60.76 94.22
F7 0 0 0 16.99 79.76 100
F8 0 0 0 11.50 66.41 97.64
F9 0 0 0 12.22 75.21 100
F10 +1 0 1 15.87 80.76 100
F11 +1 0 +1 14.88 83.34 100
F12 1 +1 0 6.54 60.76 94.43
F13 0 +1 1 13.57 71.54 100
F14 0 +1 +1 15.32 45.26 100
F15 +1 +1 0 12.76 64.34 100
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